Literature DB >> 3863717

Similar changes in cardiac morphology and DNA synthesis induced by doxorubicin and 4'-epi-doxorubicin.

K Wassermann, K Mølgaard, E Steiness.   

Abstract

Doxorubicin is an antineoplastic agent whose clinical administration is limited by dose-dependent irreversible cardiomyopathy. Doxorubicin inhibits the rate of DNA synthesis in cultured rat myocardial cells after 1 h incubation with 16 microM, as is demonstrated by a decreased incorporation of [methyl-3H]thymidine. An analogue of doxorubicin, 4'-epi-doxorubicin, also inhibits the rate of DNA synthesis within 1 h after treatment with 16 microM, to the same extent as doxorubicin-treatment of myocardial cells. Furthermore, similarity between doxorubicin and 4'-epi-doxorubicin in their effect on the myocardial thymidylate pool was also demonstrated by a significantly decreased incorporation of total [methyl-3H]thymidine. The effect of doxorubicin on the rate of DNA synthesis in cultured rat skeletal muscle cells treated for 1 h with 16 microM was quantitatively the same as in myocardial cells. Light microscopy of doxorubicin- and 4'-epi-doxorubicin-treated myocardial cells and doxorubicin-treated skeletal muscle cells showed distinct nucleolar fragmentation and revealed no differences between the two drugs in their effect on either myocardial or skeletal muscle cells. Electron microscopy of myocardial cells following doxorubicin treatment showed increased nuclear pleomorphism and invaginations, along with a striking and distinctive clumping of nuclear chromatin. Furthermore, an apparent high density of the mitochondria due to an increased matrix volume and a concomitant decrease in the intermembrane compartment were observed. The results of this study indicate that doxorubicin-induced inhibition of cardiac DNA synthesis in cultured myocardial cells is nonpredictive of cardiotoxicity. The mechanism is at least bimodal, and the apparent minor toxicity of 4'-epi-doxorubicin compared with that of doxorubicin in clinical trials cannot be distinguished by a difference in the inhibition of DNA synthesis in the rat heart.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3863717     DOI: 10.1007/bf00263895

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  Alterations in DNA synthesis in cardiac tissue induced by adriamycin in vivo-relationship to fatal toxicity.

Authors:  S H Rosenoff; E Brooks; F Bostick; R C Young
Journal:  Biochem Pharmacol       Date:  1975-10-15       Impact factor: 5.858

2.  Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity.

Authors:  S H Rosenoff; H M Olson; D M Young; F Bostick; R C Young
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

Review 3.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

4.  Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity.

Authors:  Y Iwamoto; I L Hansen; T H Porter; K Folkers
Journal:  Biochem Biophys Res Commun       Date:  1974-06-04       Impact factor: 3.575

5.  Effects of adriamycin on rat heart cells in culture: increased accumulation and nucleoli fragmentation in cardiac muscle v. non-muscle cells.

Authors:  T J Lampidis; L V Johnson; M Israel
Journal:  J Mol Cell Cardiol       Date:  1981-10       Impact factor: 5.000

6.  A stereological analysis of the effect of adriamycin on the ultrastructure of rat myocardial cells in culture.

Authors:  T P Tobin; B C Abbott
Journal:  J Mol Cell Cardiol       Date:  1980-11       Impact factor: 5.000

7.  Differential effect of adriamycin on DNA replicative and repair synthesis in cultured neonatal rat cardiac cells.

Authors:  H Fialkoff; M F Goodman; M W Seraydarian
Journal:  Cancer Res       Date:  1979-04       Impact factor: 12.701

8.  Anthracycline cardiomyopathy.

Authors:  N L Kobrinsky; N K Ramsay; W Krivit
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

9.  Effects of adriamycin on DNA synthesis in mouse and rat heart.

Authors:  F Formelli; M S Zedeck; S S Sternberg; F S Philips
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

10.  Ultrastructural changes produced in cultured, adriamycin-treated myocardial cells.

Authors:  A Necco; T Dasdia; S Cozzi; M Ferraguti
Journal:  Tumori       Date:  1976 Sep-Oct
View more
  3 in total

1.  Parameiosis in Aspergillus nidulans in response to doxorubicin.

Authors:  T C A Becker; M A A De Castro-Prado
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

Review 2.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  Doxorubicin binds in a cooperative manner to myocardial cells. Two binding sites.

Authors:  K Wassermann; E Steiness
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.